Enhancing AAV Manufacturing: Provinase™ for Efficient DNA Clearance

Enhancing AAV Manufacturing: Provinase™ for Efficient DNA Clearance

Adeno-associated viral vectors (AAVs) are central to today’s gene therapy landscape. Multiple AAV-based therapies are now approved globally, with many more in late-stage development. Yet, despite this progress, manufacturing challenges remain a key bottleneck in scaling these therapies to patients.

One of the most persistent issues lies in residual DNA. The DNA Challenge in AAV Manufacturing

During transient transfection and AAV production, large amounts of nucleic acids, plasmid backbones, host-cell DNA and RNA remain after cell lysis. Unless efficiently cleared, these contaminants can:

• Compromise product purity and safety
• Increase burden on downstream purification
• Slow regulatory approval due to strict DNA clearance limits

The Role of Provinase™

Provinase™ is a recombinant, animal-origin-free endonuclease designed for biomanufacturing applications, including AAV vector production. In downstream workflows, it enables:

• Efficient digestion of host-cell DNA and nucleic acid impurities
• Process robustness across varying conditions
• Streamlined purification, reducing overall complexity and cost
• Regulatory compliance, aligning with global expectations for advanced therapies
• Toward Smarter AAV Bioprocessing

As the field moves toward scalable and regulatory-aligned platforms, combining upstream innovations (like dbDNA for plasmid-free production) with downstream enablers (such as Provinase™ for DNA clearance) helps create more efficient, reproducible and scalable AAV manufacturing processes.

The future of AAV therapies depends not just on innovative vector design, but also on overcoming the manufacturing challenges that stand between scientific discovery and clinical impact. Provinase™ is one of the enzymatic tools helping bridge that gap.